Vertex Pharma (VRTX) Tops Q2 EPS by 3c; Reiterates Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. TMUS
6. PEP
7. AXP
8. SPY
9. CVS
10. UNH

Go back to Vertex Pharma (VRTX) Tops Q2 EPS by 3c; Reiterates Outlook

Vertex Reports Second Quarter 2016 Financial Results

July 27, 2016 4:01 PM EDT

-Second quarter 2016 cystic fibrosis product revenues of $426 million; $245 million for ORKAMBI® (lumacaftor/ivacaftor) and $180 million for KALYDECO® (ivacaftor)-

-Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 to $705 million-

-Pipeline of investigational CF medicines continues to progress and expand with addition of recent Moderna mRNA collaboration-

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2016 and reviewed recent progress with its approved and investigational cystic... More